Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis

被引:16
作者
Njei, B. [1 ,2 ]
McCarty, T. R. [3 ]
Fortune, B. E. [1 ]
Lim, J. K. [1 ]
机构
[1] Yale Univ, Sch Med, Sect Digest Dis, 333 Cedar St,LMP 1080, New Haven, CT 06520 USA
[2] Yale Ctr Clin Invest, Invest Med Program, New Haven, CT USA
[3] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA
关键词
ALPHA-2B PLUS RIBAVIRIN; GENOTYPE; INFECTION; RECURRENT HEPATITIS; UNITED-STATES; HCV INFECTION; PEGYLATED INTERFERON-ALPHA-2B; PEGINTERFERON ALPHA-2B; NATURAL-HISTORY; VIRUS-INFECTION; ANTIVIRAL THERAPY;
D O I
10.1111/apt.13798
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Recurrence of hepatitis C virus (HCV) following liver transplantation (LT) is universal for those with ongoing viraemia and is associated with higher rates of allograft failure and death. However, the optimal timing of HCV treatment for patients awaiting transplant remains unclear. Aim To evaluate the comparative cost-effectiveness of treating HCV pre-LT vs. post-LT (pre-emptive or after HCV recurrence). Methods A Markov state-transition model was created to simulate the progression of a cohort of HCV-genotype 1 or 4 cirrhotic patients from the time of transplant listing until death. We then used this model to study the cost-effectiveness of ledipasvir-sofosbuvir (LDV/SOF) with ribavirin for 12 weeks, administered for three separate treatment strategies: (i) pre-LT; (ii) post-LT preemptively prior to HCV recurrence; or (iii) post-LT after HCV recurrence. Results In the base-case analysis using a median model for end-stage liver disease (MELD) score <25 at the time of transplant, we found that pre-LT treatment of HCV led to more QALYs for fewer dollars compared to other strategies. Analysis limited to living donor LT recipients revealed that preLT treatment was also the most cost-effective strategy. When the analysis was repeated for MELD >= 25, decompensated disease (Child-Pugh class B or C), and hepatocellular carcinoma cases, preemptive post-LT strategy was more cost-effective. Conclusions Treatment of HCV prior to liver transplantation appears to be the most cost-effective strategy for patients with a MELD score <25. For patients with a MELD >= 25 or decompensated cirrhosis, preemptive post-liver transplantation treatment before HCV recurrence is the most cost-effective strategy.
引用
收藏
页码:1090 / 1101
页数:12
相关论文
共 54 条
  • [51] Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens
    Younossi, Z.
    Henry, L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (06) : 497 - 520
  • [52] Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection
    Younossi, Z. M.
    Park, H.
    Saab, S.
    Ahmed, A.
    Dieterich, D.
    Gordon, S. C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (06) : 544 - 563
  • [53] Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C
    Younossi, ZM
    Singer, ME
    McHutchison, JG
    Shermock, KM
    [J]. HEPATOLOGY, 1999, 30 (05) : 1318 - 1324
  • [54] Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
    Zhang, Sai
    Bastian, Nathaniel D.
    Griffin, Paul M.
    [J]. BMC GASTROENTEROLOGY, 2015, 15